Latest Ibritumomab tiuxetan Stories

2009-05-07 00:30:00

Pixantrone Named-Patient Program Initiated in Europe SEATTLE, May 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reported recent accomplishments and financial results for the quarter ended March 31, 2009.

2009-04-06 00:30:00

SEATTLE, April 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it received $6.5 million from Spectrum Pharmaceuticals, Inc.

2009-03-19 00:30:00

Company estimates sales of pixantrone, if approved, could potentially reach $1 billion by 2014 SEATTLE, March 19 /PRNewswire-FirstCall/ -- Craig Philips, President of Cell Therapeutics, Inc.

2009-03-16 00:30:00

Net operating expenses decreased by 33% in 2008; Forecast cutting net operating expenses by approximately 50% in 2009 CTI expects to complete pixantrone NDA submission in Q2 2009 SEATTLE, March 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.

2009-02-20 15:05:00

CTI to focus on Pixantrone and OPAXIO Approval and Commercialization SEATTLE, Feb. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.

2009-02-10 00:30:00

SEATTLE, Feb. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (NASDAQ and MTA: CTIC) today announced that they have executed a definitive collaborative agreement with IDIS to manage its investigational drug pixantrone on a named patient basis in Europe.

2009-01-22 00:30:00

SEATTLE, Jan. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today results of a study published by Esmaeli, et al.

2009-01-14 00:30:00

SEATTLE, Jan. 14 /PRNewswire-FirstCall/ -- In meetings held in association with the JP Morgan Healthcare Conference in San Francisco, Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and 2008 accomplishments.

Word of the Day
  • Stoppage; cessation (of labor).
  • A standing still or idling (of mills, factories, etc.).
The word chomage comes into English from French.]